预约演示
更新于：2025-12-27
Diclofenac Epolamine
双氯芬酸依泊胺
更新于：2025-12-27
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 英国 (2003-05-28) |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H24Cl2N2O3 |
InChIKeyDCERVXIINVUMKU-UHFFFAOYSA-N |
CAS号119623-66-4 |
关联
22
项与 双氯芬酸依泊胺 相关的临床试验CTR20244366
双氯芬酸依泊胺凝胶贴膏人体生物等效性研究
CTR20241517
双氯芬酸依泊胺贴在中国健康受试者外用条件下单次给药的人体生物等效性临床试验
CTR20232884
双氯芬酸依泊胺贴治疗局部软组织损伤（拉伤、扭伤、挫伤）引起的疼痛的有效性和安全性多中心、随机、双盲、阳性药、安慰剂平行对照临床试验
100 项与 双氯芬酸依泊胺 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸依泊胺 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸依泊胺 相关的专利（医药）
登录后查看更多信息
74
项与 双氯芬酸依泊胺 相关的文献（医药）2025-01-05JOURNAL OF COMPUTATIONAL CHEMISTRY
Article
作者: Fan, Qing ; Ning, Xiangzhen ; Zhang, Simeng ; Liu, Haichun ; Zhang, Yanmin ; Shen, Jun ; Han, Weijie ; Xu, Chengcheng ; Chen, Yadong ; Liu, Yingxu
ABSTRACT:
Identifying interactions between drugs and targets is crucial for drug discovery and development. Nevertheless, the determination of drug‐target binding affinities (DTAs) through traditional experimental methods is a time‐consuming process. Conventional approaches to predicting drug‐target interactions (DTIs) frequently prove inadequate due to an insufficient representation of drugs and targets, resulting in ineffective feature capture and questionable interpretability of results. To address these challenges, we introduce CGPDTA, a novel deep learning framework empowered by transfer learning, designed explicitly for the accurate prediction of DTAs. CGPDTA leverages the complementarity of drug–drug and protein–protein interaction knowledge through advanced drug and protein language models. It further enhances predictive capability and interpretability by incorporating molecular substructure graphs and protein pocket sequences to represent local features of drugs and targets effectively. Our findings demonstrate that CGPDTA not only outperforms existing methods in accuracy but also provides meaningful insights into the predictive process, marking a significant advancement in the field of drug discovery.
2023-10-01Pain and therapy
Treatment Satisfaction, Efficacy, and Tolerability of Low-Dose Diclofenac Epolamine Soft Capsules in Acute, Mild, or Moderate Musculoskeletal Pain: A Prospective Open-Label, Single-Arm Interventional Study.
Article
作者: Trevisan, Carlo L M ; Carraro, Andrea ; Baldari, Gemma L A
INTRODUCTION:
The use of oral nonsteroidal anti-inflammatory drugs (NSAIDs) for acute musculoskeletal pain should be at the lowest effective dosage and for the shortest duration to minimize potential adverse effects. This study evaluated treatment satisfaction, effectiveness, and tolerability of a low-dose diclofenac epolamine 12.5-mg soft capsule formulation (DHEP 12.5-mg capsules) using patient-reported outcome measures in a real-life setting over a short period (3 days) in subjects with mild-to-moderate acute musculoskeletal pain.
METHODS:
A prospective, open-label, phase IV clinical study in adult outpatients at hospital clinic departments/general practitioner's clinics at eight sites in Italy. The primary efficacy variable was the degree of satisfaction with treatment at 72 ± 7 h after initiation of treatment, assessed using the Overall Satisfaction Question of the Pain Treatment Satisfaction Scale (PTSS) and described by classic descriptive statistics. Secondary objectives were to evaluate the analgesic effect after the first administration and over time; the time to and satisfaction with the onset of pain relief, amount of and duration of pain relief; pain intensity differences over time; and safety and tolerability. The investigator's satisfaction with the treatment was also assessed. Subjects initially took 1-2 capsules of the study treatment and then one or two soft capsules every 4-6 h according to their needs. Not more than six soft capsules were to be taken in any 24-h period.
RESULTS:
A total of 182 subjects (mean age, 56.2 years; 54.4% female) took ≥ 1 dose of DHEP capsule and were included in the full analysis set. The most common musculoskeletal conditions were arthralgia (39.0%) and low back pain (23.1%). All subjects completed the study, and 165/182 (90.7%, 95% CI 0.86, 0.95) were satisfied or very satisfied with the treatment at 72 ± 7 h after the first dose (primary efficacy variable). Similar percentages were recorded for treatment satisfaction concerning other efficacy parameters. The onset of the analgesic effect was rapid, with complete pain relief reached after a mean of 49.45 min. Investigators rated their overall treatment satisfaction as 92.9%. Treatment was well tolerated.
CONCLUSIONS:
The low-dose (12.5 or 25 mg) oral diclofenac epolamine soft capsules formulation exerted rapid, effective, and safe analgesic activity in patients with mild-to-moderate musculoskeletal pain, with subjects' overall satisfaction with treatment more than 90%.
TRIAL REGISTRATION:
EudraCT Number: 2018-004886-15 (Study 18I-Fsg08). Registered 04/09/2018.
2022-11-01Biomaterials advances
Effect of microneedles shape on skin penetration and transdermal drug administration
Article
作者: Palladino, Antonio ; De Martino, Selene ; Amendola, Eugenio ; Napolitano, Francesco ; Serpico, Luigia ; De Stefano, Luca ; Squillace, Antonino ; De Girolamo, Paolo ; Battisti, Mario ; Martone, Alfonso ; Dardano, Principia ; Dello Iacono, Stefania
Microneedle (MN) patches are highly efficient and versatile tools for transdermal drug administration, in particular for pain-free, self-medication and rapid local applications. Diffraction ultraviolet (UV) light lithography offers an advanced method in fabricating poly(ethylene glycol)-based MNs with different shapes, by changing both the UV-light exposure time and photomask design. The exposure time interval is limited at obtaining conical structures with aspect ratio < 1:3, otherwise MNs exhibit reduced fracture load and poor indentation ability, not suitable for practical application. Therefore, this work is focused on a systematic analysis of the MN's base shapes effects on the structural characteristics, skin penetration and drug delivery. Analyzing four different base shapes (circle, triangle, square and star), it has been found that the number of vertices in the polygon base heavily affects these properties. The star-like MNs reveal the most efficient skin penetration ability (equal to 40 % of -their length), due to the edges action on the skin during the perforation. Furthermore, the quantification of the drug delivered by the MNs through ex-vivo porcine skin shows that the amounts of small molecules released over 24 h by star-like MNs coated by local anesthetic (Lidocaine) and an anti-inflammatory (Diclofenac epolamine) drugs are 1.5× and 2× higher than the circular-MNs, respectively.
100 项与 双氯芬酸依泊胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2007-01-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 挫伤 | 临床3期 | 中国 | 2023-11-15 | |
| 疼痛 | 临床3期 | 中国 | 2023-11-15 | |
| 扭伤和拉伤 | 临床3期 | 中国 | 2023-11-15 | |
| 软组织损伤 | 临床3期 | 美国 | 2021-10-31 | |
| 膝关节炎 | 临床前 | 美国 | 2022-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 658 | Placebo | 齋鹹鹹願壓衊糧艱觸蓋(廠淵艱築餘繭範選範糧) = 糧繭積遞衊觸築齋鹹願 衊夢選鹹糧餘淵製齋選 (積餘艱艱網鹽鹽衊衊築, 11.37) 更多 | - | 2020-06-24 | ||
早期临床1期 | - | 12 | (Diclofenac Epolamine Patches) | 鏇淵窪淵繭淵範膚簾願(艱蓋網夢獵構襯鹽鑰繭) = 積顧獵壓鬱範醖鏇衊繭 願膚壓觸觸艱觸淵衊衊 (獵夢窪願簾鑰範糧顧齋, 10.8) 更多 | - | 2020-06-16 | |
(Diclofenac Sodium Solution) | 鏇淵窪淵繭淵範膚簾願(艱蓋網夢獵構襯鹽鑰繭) = 衊糧繭鬱選餘遞糧壓淵 願膚壓觸觸艱觸淵衊衊 (獵夢窪願簾鑰範糧顧齋, 54.3) 更多 | ||||||
临床4期 | 104 | (Flector Patch/Age 6-11) | 鏇獵顧鏇夢憲選網積積(網鏇餘網餘製鹹獵鏇顧) = 糧淵觸鏇艱簾餘壓蓋糧 顧遞夢顧範鹽蓋範壓鹹 (積鏇繭選簾鬱鑰衊廠顧, 0.30) 更多 | - | 2018-05-11 | ||
(Flector Patch/Age 12-16) | 鏇獵顧鏇夢憲選網積積(網鏇餘網餘製鹹獵鏇顧) = 網醖齋蓋繭醖壓廠鹽願 顧遞夢顧範鹽蓋範壓鹹 (積鏇繭選簾鬱鑰衊廠顧, 0.19) 更多 | ||||||
临床4期 | 123 | 積醖艱鹹襯鹹製憲鬱壓(製鬱顧願構鑰範蓋簾壓) = 築襯鑰製窪壓壓繭獵憲 壓壓醖鹽齋鑰鬱衊製積 (遞顧壓製顧膚齋簾衊鬱, 1.30) 更多 | - | 2012-08-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用